Related Experiment Video
Updated: Mar 29, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy
A Borah1, S Raveendran1, A Rochani1
1Bio Nano Electronics Research Center, Graduate School of Interdisciplinary New Science, Toyo University, Kawagoe, Saitama, Japan.
Abstract:
Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy.
Insights
Cancer stem cells (CSCs) drive tumor growth and recurrence due to deregulated self-renewal pathways (SRPs). Targeting these SRPs with nanoformulations offers a promising strategy to improve cancer therapy by enhancing drug delivery and reducing side effects.
Area of Science:
- Oncology
- Cancer Biology
- Nanotechnology
Background:
- Cancer stem cells (CSCs) are a rare subpopulation driving tumorigenesis and metastasis.
- CSCs possess deregulated self-renewal pathways (SRPs), conferring resistance to conventional chemotherapy and leading to tumor recurrence.
- Current cancer treatments struggle to differentiate and target CSCs effectively due to a lack of specific biomarkers.
Purpose of the Study:
- To investigate the complex functional biology of CSCs, focusing on signaling pathways.
- To explore novel therapeutic strategies targeting SRPs in CSCs for improved cancer treatment.
- To evaluate the potential of nanoformulations in selectively targeting CSC-specific pathways.
Main Methods:
- Review of existing cancer research on CSCs and their self-renewal mechanisms.
- Analysis of signaling pathways implicated in CSC survival and drug resistance, including Hedgehog, Wnt, Notch, and B-cell-specific moloney murine leukemia virus integration site 1.
- Exploration of nanoformulation strategies for targeted delivery of therapeutic agents to CSCs.
Main Results:
- Deregulated SRPs in CSCs are critical for their survival, tumorigenesis, and resistance to chemotherapy.
- Direct targeting of SRPs with small molecules presents challenges including off-target effects, poor bioavailability, and severe side effects.
- Nanoformulations show potential for selective targeting of SRPs in CSCs, sparing normal stem cells.
Conclusions:
- Targeting deregulated SRPs in CSCs is a promising strategy to overcome therapeutic resistance and prevent tumor recurrence.
- Nanoformulations offer an advantageous approach to deliver therapeutic agents selectively to CSCs, mitigating the limitations of conventional methods.
- A comprehensive understanding of CSC molecular pathways combined with holistic nanosystems could revolutionize future cancer therapy.
Related Concept Videos
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Renewal of Skin Epidermal Stem Cells
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

